Article
Performance of serological tests available in Brazil for the diagnosis of human visceral leishmaniasis
Registro en:
FREIRA, Mariana Lourenço et al. Performance of serological tests available in Brazil for the diagnosis of human visceral leishmaniasis. PLoS Neglected Tropical Diseases, v. 13, n. 7, p. 1-12, 2019.
1935-2727
10.1371/journal.pntd.0007484
Autor
Freire, Mariana Lourenço
Assis, Tália Machado de
Oliveira, Edward
Avelar, Daniel Moreira de
Siqueira, Isadora Cristina de
Barral, Aldina Maria Prado
Rabello, Ana
Cota, Gláucia
Resumen
Coordenação de
Aperfeiçoamento de Pessoal de Nível Superior
(CAPES), Brasil – Finance Code 001. Visceral leishmaniasis (VL) is the most severe form of leishmaniasis and is potentially fatal if not diagnosed and treated. Accurate and timely diagnosis is considered one of the pillars needed for the reduction in disease-related lethality. Brazil is currently one of the three eco-epidemiological hotspots for this disease. Several serological tests are commercially available in this country for VL diagnosis, although information on the performance of these tests is fragmented and insufficient. The aim of this study was to directly compare the performance of six commercial kits: three enzyme-linked immunosorbent assays (ELISAs), two immunofluorescence antibody tests (IFATs), one immunochromatographic test (ICT), besides one ICT, currently not commercially available in Brazil and one in-house direct agglutination test (DAT-LPC), not yet marketed.